Voyager Therapeutics, Inc. (NASDAQ:VYGR) Sees Significant Decline in Short Interest

Voyager Therapeutics, Inc. (NASDAQ:VYGR) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 2,440,000 shares, a decline of 17.3% from the October 31st total of 2,950,000 shares. Based on an average daily volume of 562,900 shares, the days-to-cover ratio is presently 4.3 days.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Wedbush began coverage on shares of Voyager Therapeutics in a research note on Friday. They set an “outperform” rating and a $11.00 price target for the company. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Buy” and an average target price of $17.50.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its position in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares during the last quarter. SummerHaven Investment Management LLC raised its stake in Voyager Therapeutics by 2.5% in the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock valued at $611,000 after acquiring an additional 1,921 shares during the period. Hunter Perkins Capital Management LLC lifted its holdings in Voyager Therapeutics by 3.3% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares during the last quarter. Empowered Funds LLC boosted its position in Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after purchasing an additional 2,278 shares during the period. Finally, Federated Hermes Inc. boosted its position in Voyager Therapeutics by 0.5% during the second quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after purchasing an additional 2,638 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 18.7 %

NASDAQ:VYGR opened at $6.86 on Friday. The stock has a market capitalization of $374.73 million, a PE ratio of 9.66 and a beta of 0.89. Voyager Therapeutics has a 1-year low of $5.19 and a 1-year high of $11.72. The firm has a fifty day simple moving average of $6.51 and a 200 day simple moving average of $7.31.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the firm posted ($0.59) EPS. On average, equities analysts predict that Voyager Therapeutics will post -1.03 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.